Core Insights - The event "Hand in Hand with Hong Kong, Discussing the Future" was successfully held in Hong Kong, organized by Shuangyi Pharmaceutical and RaffAello, focusing on corporate development, industry trends, and investment opportunities [1][3] - Chairman Wang Bo emphasized that 2026 is a critical year for Shuangyi Pharmaceutical's transformation and high-quality development, aiming to leverage Hong Kong's international financial advantages to showcase Guangxi's achievements and promote key products globally [3][5] Company Strategy - Shuangyi Pharmaceutical is committed to implementing a "dual brand" strategy, aiming to establish its flagship product, Shuangyi Qushi Tongluo Capsule, as a global leader while also striving to make its compound cold medicine granules a market champion [5] - The company plans to expand its business both domestically and internationally, focusing on product-centric and market-oriented approaches, with a vision to enhance collaboration with partners for broader development opportunities [5] Industry Reception - Attending fund managers praised Shuangyi Pharmaceutical's dedication to ethnic Zhuang medicine and its commitment to independent innovation, recognizing the company's growth journey as a testament to resilience and potential [5] - The overall atmosphere of the event was positive, with deep exchanges and interactions, reflecting the company's commitment to its corporate spirit of unity, diligence, perseverance, and innovation [6]

Core Viewpoint - The research team from Beijing Normal University visited Guangxi Shuangyi Pharmaceutical Co., Ltd. to study the development of ethnic medicine and its industrialization in the context of regional development in ethnic areas [1] Group 1: Company Overview - Guangxi Shuangyi Pharmaceutical is recognized as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Guangxi [7] - The company has developed a unique product, the Shuangyi Dampness-Removing Capsule, which is the first recognized Zhuang medicine, utilizing traditional Zhuang medical formulas and modern production techniques [3][8] Group 2: Product Development and Quality - The company emphasizes quality control, with internal standards exceeding national requirements, reflecting its commitment to public health [3] - The annual sales of the compound cold medicine granules exceed 100 million, showcasing the company's successful product line in the Zhuang medicine sector [3] Group 3: Research and Development - The company has established the "Guangxi Zhuang Autonomous Region Medicinal Animal Engineering Research Center," focusing on the research and development of Zhuang and Yao medicines, and holds multiple invention patents [8] - The integration of traditional medicine with modern technology is a key strategy for the company, aiming to modernize ethnic medicine [8] Group 4: Community Engagement and Sustainability - The company employs a "company + cooperative + farmer" model to promote the cultivation of Zhuang and Yao medicinal materials, supporting local communities and ensuring a stable supply of raw materials for production [5] - The establishment of a dedicated medicinal material planting base in the "World Yao Capital" Jinxi Yao Autonomous County enhances the scale and standardization of Zhuang and Yao medicinal resources [5] Group 5: Future Goals - The company aims to continue promoting Zhuang and Yao medical culture, deepen industry-academia-research cooperation, and establish itself as a leader in the production of anti-cold and rheumatism medications in China [10] - The long-term goal is to contribute significantly to the modernization of ethnic regions through the development of the ethnic medicine industry [10]

Core Viewpoint - The collaboration between Guangxi Shuangyi Pharmaceutical Co., Ltd. and Hubei Jinying Agricultural Development Co., Ltd. aims to enhance the quality and stability of the core raw material, wild chrysanthemum, for Shuangyi's flagship product, Shuangyi Compound Cold Medicine Granules, through standardized planting techniques and a comprehensive supply chain [1][9]. Group 1: Company Collaboration - The visit by Shuangyi's chairman and vice president to Hubei Jinying was focused on exploring the entire supply chain of wild chrysanthemum, including breeding, large-scale cultivation, and processing [1][3]. - Hubei Jinying has established a complete industrial chain for traditional Chinese medicine, with 2,580 acres of medicinal herb cultivation, including 1,030 acres dedicated to wild chrysanthemum [6]. - Shuangyi Pharmaceutical recognizes the advantages of Hubei Jinying's breeding and cultivation techniques, expressing a strong intention to introduce these methods to enhance its own herbal medicine cultivation base [9][11]. Group 2: Product Quality and Market Demand - Wild chrysanthemum is a key ingredient for Shuangyi's products, which include various cold and cough remedies, indicating a significant market demand for this raw material [8]. - The use of Hubei's wild chrysanthemum not only improves the efficacy of Shuangyi's products but also strengthens its competitive edge in the market [9]. - Shuangyi emphasizes its commitment to using authentic medicinal materials, which is crucial for maintaining product quality, especially in light of the recent increase in influenza cases [13]. Group 3: Future Cooperation and Development - The visit established a communication bridge for future collaboration, with both companies aiming to explore new cooperation models that promote resource sharing and complementary advantages [15]. - The partnership is expected to contribute to the high-quality development of the traditional Chinese medicine industry and support rural revitalization efforts [15].

Core Insights - The company, Shuangyi Pharmaceutical, achieved significant recognition at the 19th Growth Conference, winning awards across three dimensions: enterprise, leadership, and product, showcasing its comprehensive strength and industry influence [1][2]. Group 1: Company Achievements - Shuangyi Pharmaceutical was awarded the "Partner" title for its outstanding supply chain collaboration and channel co-construction achievements [1]. - The company’s booth attracted numerous attendees for discussions, highlighting its brand appeal and influence in the industry [2]. Group 2: Leadership Recognition - Chairman Wang Bo received the "Innovator in Business Model" award for his strategic vision and innovative business model capabilities [2]. Group 3: Product Recognition - The company's key product, "Shuangyi Qu Shi Tong Luo Capsules," was recognized as a "Recommended Product" due to its effective therapeutic results and broad market acceptance [2]. Group 4: Future Outlook - Shuangyi Pharmaceutical aims to use this recognition as a new starting point to deepen cooperation, promote innovation, and optimize products, collaborating with partners to achieve higher quality development [2].